Idorsia to present new Phase 3 data on daridorexant in insomnia at SLEEP 2021

NEXT STORY
Stem Cell Manufacturing Market Size to Reach USD 28.85 Billion in 2028: Reports and Data
PREV STORY
A Comprehensive Analysis of 18+ Key Companies Strengthening Chronic Spontaneous Urticaria Pipeline | Insights by DelveInsight
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

REGENXBIO Announces IND Active for Phase I/II Trial of RGX-121 to Treat Mucopolysaccharidosis Type II

Novel, one-time, direct-to-CNS treatment for MPS II focused toward potentially preventing the progression of ...

author_avatar
NASDAQ Market News

Biogen Presents Data at 2019 AAN Annual Meeting Affirming Longer-Term Safety and Durability of Treatment with SPINRAZA® (nusinersen)

author_avatar
NASDAQ Market News

Madrigal Pharmaceuticals Announces Support of Fatty Liver Foundation’s Screening Fund to Improve Diagnosis and Staging of Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH)

author_avatar
NASDAQ Market News